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ABSTRACT
OBJECTIVES: Hereditary Breast and Ovarian Cancer (HBOC) is an autosomal dominant
cancer predisposition syndrome with a 46-87% lifetime risk of breast cancer. Unaffected
women who have HBOC are eligible for more screening procedures and prophylactic
surgeries that may reduce the risk of developing cancer by up to 95%. The objectives of
this study were to assess women’s awareness of and interest in breast cancer genetic
testing services, as well as women’s attitudes and beliefs regarding the clinical utilization
of HBOC genetic testing across demographic categories. METHODS: Two-hundred and
sixty-eight women completed a 35-item survey designed to capture perceptions of HBOC
and genetic testing, attitudes towards genetic testing for HBOC, and demographics.
RESULTS: Two-hundred and eight women met participation criteria. One-hundred and
fifty-five (75%) indicated prior awareness of genetic testing services. One-hundred and
forty-three (69%) indicated interest in genetic testing for HBOC. Black women, women
with lower levels of education, and women with lower household incomes reported less
awareness, but similar levels of interest in genetic testing services when compared to
other participants. CONCLUSIONS: Women are interested in genetic testing for HBOC.
Specific counseling on barriers to minority and low socioeconomic communities, such as
cost and education regarding genetic testing procedures, may be beneficial in increasing
utilization of genetic testing for HBOC in these communities. Women who experience
more discrimination may have increased perceptions of their susceptibility to hereditary
cancer syndromes and may benefit from personalized risk counseling.
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CHAPTER I. BACKGROUND
Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant cancer
predisposition syndrome caused by germline mutations in the breast cancer 1 (BRCA1)
and breast cancer 2 (BRCA2) tumor suppressor genes. Individuals who have a pathogenic
gene mutation in BRCA1 or BRCA2 have a 46-87% life time risk of developing breast
cancer, compared to a general population risk of 12% (National Comprehensive Cancer
Network, 2016). A prophylactic bilateral mastectomy in mutation carriers has been found
to reduce the risk of breast cancer by at least 90% (Hartmann et al., 1999). An estimated
5-10% of all breast cancer cases are attributable to an inherited mutation (National
Cancer Institute, 2015).

1.1 Hereditary Breast Cancer
Breast cancer is a cancer that develops from breast tissue. In the general population,
one in eight women will develop breast cancer at some point in their lives, making it the
second most common cancer in women (National Cancer Institute, 2014). The incidence
of breast cancer has risen over the past 30 years, most frequently affecting white and
black women (National Cancer Institute, 2013). Despite the high prevalence of diagnoses
of breast cancer in white women, they are statistically the least likely to die once
diagnosed with breast cancer (National Cancer Institute, 2013). Black women are more
likely to be diagnosed at a later stage of breast cancer, and to die due to breast cancer
(Siegal, 2015). Besides ethnicity, Some of the risk factors for developing breast cancer
1

include older age, higher breast density, a history of radiation therapy, a family or
personal history of breast cancer, and genetic changes that predispose individuals to the
development of breast cancer (National Cancer Institute, 2015).
Five to ten percent of all breast cancer cases are classified as ‘hereditary’,
meaning that they are caused by an inherited genetic mutation that raises the risk of
cancer development by ceasing or altering the function of cancer-preventing proteins
(National Cancer Institute, 2016). The two most common genetic causes of breast cancer
are the BRCA1 and BRCA2 genes, which are implicated in 20-25% of hereditary breast
cancer cases (Pharoah et al., 2002). The prevalence of BRCA carriers in the general
population is estimated to be 1 in 200-400. However, this estimate is based on data from
breast cancer patient populations and may not reflect the true carrier frequency in the
general population (Metcalfe et al., 2015).
When functioning properly, the BRCA genes work to produce proteins that repair
damage to DNA and regulate transcription. When there are mutations in a BRCA gene, it
results in the formation of a truncated protein that is unable to regulate cell growth,
leading to tumorigenesis (Welcsh & King, 2001). Mutations in the BRCA genes are
associated with an estimated 46-87% lifetime risk of developing breast cancer, markedly
higher than the 12% risk an average woman has of developing breast cancer (National
Comprehensive Cancer Network, 2016). Currently, researchers have identified a network
of over nine genes, including BRCA1 and BRCA2, that are each implicated in raising the
risk of developing breast cancer to at greater than 20% (National Comprehensive Cancer
Network, 2016).
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The vast majority of genetic changes implicated in hereditary breast cancer are
inherited in an autosomal dominant pattern, meaning only one mutated copy of the two
genes is required to cause a person to have an increased risk of cancer. However,
tumorigenesis only occurs when both copies of the gene are pathogenically mutated. This
happens naturally, or somatically, as a person ages either through errors in DNA
replication or through environmental exposures such as tobacco smoke or UV light. In
persons with no inherited change, both genes will have been somatically mutated
throughout their life to cause cancer development. In persons with an inherited mutation
in a cancer-susceptibility gene, only one detrimental environmental event that
pathogenically harms the DNA of the un-mutated copy of the gene permanently is needed
to cause the onset of tumorigenesis, a phenomenon termed the ‘Knudson Two-Hit
Hypothesis’ (Anderson, 1992). Consequently, patients with an inherited mutation in a
cancer-susceptibility gene tend to develop cancer at a younger age and at a greater
frequency than those with no inherited mutation (Burke et al., 1997).

1.2 Hereditary Breast Cancer Screening
Women who are determined to have a high risk of developing breast cancer,
either through a known genetic mutation or an extensive family history, are eligible for
and encouraged to seek high-risk screening procedures to decrease this risk (National
Comprehensive Cancer Network, 2016). These procedures involve earlier and more
frequent utilization of physical examinations and imaging techniques (National
Comprehensive Cancer Network, 2016). These screening techniques have been shown to
detect a larger number of cases of breast cancer at an earlier stage of the disease
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(DeSantis et al., 2013; Berg et al., 2012). Women who are considered to have a high risk
of developing breast cancer may also elect to have risk reducing procedures such as a
prophylactic mastectomy, which has been shown to reduce the risk of breast cancer by as
much as 90-95% (Rebbeck et al., 2004). Compared to other cancers, breast cancer has a
low mortality rate, as approximately 89.7% of women who develop breast cancer will
still be alive five years after their initial diagnosis (National Cancer Institute, 2014).

1.3 Genetic Testing for Hereditary Breast Cancer
The BRCA1 gene was first sequenced in 1994 in a collaborative effort by Myriad, a
genetic researching company, the University of Utah, the National Institute of Health,
and McGill University (Williams-Jones, 2002). Shortly after, Myriad filed for
‘composition-of-matter’ and ‘methods-of-use’ patents on the BRCA1 gene, preventing
other genetic researching institutions from sequencing the BRCA1 gene for commercial
use (Williams-Jones, 2002). The sequencing of BRCA2 quickly followed and once again,
Myriad was among the first to file a U.S. patent on the gene (Williams-Jones, 2002).
Subsequently, Myriad gained control over the commerical market for genetic testing for
all of the known hereditary breast cancer genes at the time.
The first commercial genetic test for hereditary breast cancer was BRACAnalysis,
produced and marketed by Myriad in 1996 (Williams-Jones, 2002). Myriad used their
control on the BRCA testing market to merge their testing service into multiple facets of
health care and cancer research, partnering with various health insurance companies and
institutions to allow the test to be covered by health insurance providers and accessible
for research, at a price (Williams-Jones, 2002).
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There was initial backlash against the commercialization of BRCA sequencing,
with the opposition fearing that the test was less focused on the prevention of breast
cancer and more focused on increasing patient anxiety and the creation of demand for the
product (Williams-Jones, 2002). Furthermore, Myriad’s patent on BRCA testing created
barriers to clinical care and delays in research, leading to less effective and efficient
testing at increased cost, ultimately creating wider health disparity gaps (Offit et al.,
2013). Myriad’s patent was eventually overturned by the Supreme Court in 2013,
opening the commercial market for hereditary cancer testing and promoting greater
accessibility to these tests.
Genetic testing for a hereditary breast cancer mutation can be beneficial to the
patient in multiple ways. If a patient has already been diagnosed with breast cancer,
genetic testing can help inform her treatment. A positive result for a mutation in a cancer
susceptibility gene may encourage her to opt for a double-mastectomy to reduce her
likelihood of developing a secondary cancer, as opposed to a cancer-removing
lumpectomy, which would leave behind more breast tissue and increase the risk of
recurrence (Wevers, 2014). In any patient with a family history of breast cancer,
personally affected or not, knowledge of whether or not there is a hereditary mutation in
the family can alter reproductive planning and help inform other family members if they
are at risk as well (Donnelly et al., 2013). Unaffected patients who test positive for a
mutation that increases their risk of developing breast cancer are eligible to begin
following high-risk screening regimens to promote early detection of cancer if it does
develop, and may begin to consider risk-reducing surgeries, like prophylactic
mastectomies, to decrease their chance of ever having cancer (Scheuer et al., 2002).
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Receiving genetic testing, whether the result is positive or negative, has been shown to
increase utilization of mammography and breast self-exams after result disclosure
(Botkin et al., 2003). Furthermore, women who know they have a mutation in the BRCA2
gene are eligible to begin taking Tamoxifen, a chemoprevention drug that reduces the risk
of breast cancer in women with BRCA2 mutations by approximately 62% (King et al.,
2001).
1.3.1 Patient Preferences
The impact of receiving a positive result for a BRCA mutation has been shown to
have variable psychological impacts. Studies have suggested that a positive genetic
testing result for a hereditary cancer syndrome initially leads to an increase in both
general and cancer-specific anxiety for women with BRCA1 or BRCA2 mutations, but
that this distress tends to subside significantly with time (Beran et al., 2008; WilderSmith et al., 2007). Women who report more intense emotional representations of
hereditary cancer and difficulty understanding hereditary cancer are more likely to
experience distress regarding hereditary cancer testing (Voorwinden & Jaspers, 2015).
Women cite many reasons as potential influences to sway them from pursing
genetic testing. Fear of discrimination or stigmatization by employers and health
insurance companies by use of genetic information has historically been an influence on
the decision to pursue genetic testing (Apse et al., 2004; Durfy et al., 1999). Women who
perceive themselves to have a lower risk of developing cancer are less likely to accept an
offer of genetic testing (Culver et al., 2001).
Women’s decisions to undergo genetic testing for a hereditary cancer syndrome
are complicated, with many factors influencing their reasoning for whether or not they
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should pursue testing. Women who have children or a mother with a cancer history are
more likely to choose to have testing sooner than those who do not (Hesse-Biber & An,
2016). Women also tend to factor in social factors when making decisions concerning
their genetic testing and management (Hesse-Biber & An, 2016). Women are more likely
to postpone genetic testing if they perceive themselves to have strong social supports
(Hesse-Biber & An, 2016). For women who are not yet affected, the decision to pursue
genetic testing for an adult-onset disease such as hereditary breast cancer is hypothesized
to partially be a coping mechanism to combat the uncertainty of living at risk of
developing a disease at some point in the future and to obtain control over an otherwise
minimally controllable situation (Gooding et al., 2005)
1.3.2 Patient Demographics
Education has been found to be a predictor of women’s awareness of and interest
in genetic testing for hereditary cancer syndromes. Women who obtain higher levels of
education are more likely to report awareness of genetic testing services for cancer (Mai
et al., 2014; Tambor, Rimer, & Strigo, 1998). Reported interest in pursuing genetic
counseling and testing services is also associated with higher levels of education (Culver
et al., 2001; Lerman et al., 1994).
There are significant differences in the ethnic composition of women who choose
to pursue genetic testing for cancer. Ethnic minorities are less likely to be aware of
genetic testing services and less likely to refer themselves to genetic counseling (Mai et
al., 2014; Glenn, Chawla, & Bastani, 2012; Hutson, 2003). While it is hypothesized that
the mutation prevalence of the BRCA genes is similar across ethnicities, women of
European ancestry make up the majority of consumers of genetic testing services, while
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women of African, Asian, and Latina ancestry comprise a smaller portion, even when
their numbers are combined (Hall et al., 2009; Susswein et al., 2008). Minority women
tend to face more socioeconomic barriers to accessing genetic services, such as time
limitations, difficulty accessing providers and referrals, geographic barriers, and language
barriers (Forman & Hall, 2009; Thompson et al., 2003). Ethnicity and race also play a
role on women’s attitudes and perspectives on cancer genetic testing. Minority
populations typically have greater levels of distrust in the medical community. Latina
and African American women have previously been shown to be more concerned about
testing abuses of genetic information when compared to Caucasian women (Glenn,
Chawla, & Bastani, 2012; Thompson et al., 2003).
Income and insurance coverage both play a role in determining how likely a
woman is to pursue genetic testing. Women who have higher income and utilize some
form of health insurance are more likely to have had genetic testing (Lerman et al., 1996).
Women who have lower incomes are more likely to agree with perceived disadvantages
of genetic testing, such as fear of confidentiality, concern about the impact the result may
have on the family, and a fear of being singled out, among others (Thompson et al.,
2003). Recent research has suggested that women in low income communities are
interested in receiving genetic counseling and testing, but face challenges related to
access (Komenaka et al., 2015).
Whether a person lives near an urban community or within a rural community
predicts their awareness of and access to genetic testing services. Physicians in rural
practices are less likely to refer for hereditary breast cancer than physicians practicing in

8

urban or suburban locations, due to distance, lack of awareness, lack of effective cancer
risk reduction, and lack of patient interest (Koil et al., 2003).

1.3.3 Genetic Testing: Climate Changes Impacting Awareness and Interest
The Genetic Information Nondiscrimination Act (GINA) was approved in 2008.
The main purpose of GINA was to prevent insurance companies and employers from
discriminating based on genetic testing results (Feldman, 2012). Violations of GINA are
punishable by monetary penalty. (Erwin, 2008). Misuse of genetic testing in the 1970s to
discriminate against African Americans with sickle cell disease in the workplace and
through insurance coverage fostered a mistrust of the clinical use of genetic information,
and still remains a serious concern of many citizens today (Feldman, 2012). GINA was
developed to encourage patients to receive genetic testing when it is deemed to be a
helpful investigative tool to manage their health care, without fear of this information
being used against them in the future. While knowledge about GINA is associated with a
reduction in concern regarding health insurance discrimination, consumer knowledge
about GINA is still limited (Allain, Friedman, & Senter, 2012).
The Patient Protection and Affordable Care Act (ACA) became law in 2010, and
was fully implemented on January 1, 2014. One of the main purposes of the ACA was to
guarantee access to universal, affordable, health insurance coverage. In 2007, an
estimated 56 million American citizens were considered “medically disenfranchised”,
meaning that their most basic health and wellness needs were not being met (National
Association of Community Health Centers, 2007). The ACA is projected to double the
number of patients who are medically served (Rosenbaum, 2011). Furthermore, the ACA
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allows for the reduction of the cost and the provision of Medicaid coverage for clinical
preventative services, including advanced screening and genetic counseling and testing
for women who are at high risk of developing breast cancer. (Koh & Sebelius, 2010).
However, the ACA does not provide coverage for all screening techniques recommended,
even for women with a known BRCA1/2 mutation, raising concerns that the coverage of
genetic testing alone would have limited benefit in vulnerable populations (Walcott et al.,
2014).
In 2013, awareness of genetic testing, for the BRCA genes specifically, increased
dramatically due to media coverage of celebrity Angelina Jolie’s essay sharing her
experiences with genetic testing and her subsequent decision to have a prophylactic
mastectomy (Evans et al., 2014). The aftermath of this event led to global increases in
referrals to genetic testing services and in requests for BRCA1/2 testing (Evans et al.,
2014). Women who identified with Jolie in some way were found to be especially
motivated to pursue genetic testing (Kosenko, Binder, & Hurley, 2016). In general,
research suggests that celebrity experience and endorsement raises positive public
perception of the subject and increases information seeking behaviors (Hoffman & Tan,
2013).
Studies have suggested that up to 50% of female BRCA mutation carriers have no
significant family history of suggestive of HBOC (Moller et al., 2007). Based on current
guidelines, these females would not be considered suitable candidates for genetic testing
until they themselves had an early cancer diagnosis, removing the option of prophylactic
action. Population screening for BRCA1/2 has been proposed as a possible alternative to
capture this population (Gabai-Kapara et al., 2014). Population screening has been
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shown to be more cost-effective than family-history based approaches, but will still prove
to be a costly and time-consuming process in a multi-million-person population such as
the United States (Manchanda et al., 2015; Clain et al., 2015). General population
screening of BRCA1 and BRCA2 may be a cost effective option to identify carriers, and
seems to be a possibility within our grasp as small-scale implementations are already in
effect (Wang, 2016).

1.4 Health Belief Model
The Health Belief Model (HBM) was created out of psychological and behavioral
theory in 1952 as a measure to assess factors impacting the utilization of preventative
health services, such as screening and immunizations (Rosenstock, 1974). The original
HBM consisted of four key dimensions – perceived susceptibility of developing a
condition, perceived severity of the condition, perceived benefits of preventative action
and perceived barriers to preventative action (Janz & Becker, 1984). The interactions of
each component are summarized in Figure 1.
Perceived susceptibility encompasses a range of perceptions of risk from complete
denial to imminent risk (Strecher & Rosenstock, 1997). Some individuals without a
family history of breast cancer may not feel that they are susceptible to cancer
themselves. Other individuals with a family history of breast cancer may feel that they
are highly likely to develop breast cancer themselves. Perceived severity is defined as an
individual’s assessment of the impact a diagnosis or condition may have on their lifestyle
and emotional being (Strecher & Rosenstock, 1997). Perceived benefits, or the positive
aspects of particular actions, may include physical and psychosocial gains and may
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Figure 1.1 The Health Belief Model (Becker, 1974)
influence actions related to management (Strecher & Rosenstock, 1997). Lastly,
perceived barriers, or the negative aspects of an action, may include financial costs,
inconvenience, or pain incurred by the action and also may influence actions (Strecher
&Rosenstock, 1997). Previous studies utilizing the HBM to examine women’s attitudes
and perceptions towards BRCA1/2 testing have shown a relationship between perceived
susceptibility, perceived severity, and concerns about being a mutation carrier with
testing decisions (Wang et al., 2007). Women who tend to be more concerned about
being mutation carriers, and report high perceived susceptibility and low perceived
severity were found to be more likely to undergo genetic testing (Wang et al., 2007).
Women who perceived the benefits of testing to be high were more likely to pursue
genetic testing that women who perceived the benefits of testing to be low (Wang et al.,
2007).
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In the HBM, perceived susceptibility and severity are thought to motivate an
individual to action. The reduction of perceived barriers is thought to provide easier
accessibility for an action. If an individual believes they are at high risk for a health
issue, such as developing breast cancer, an action to reduce risk is not likely to take place
unless the individual believes there are substantial benefits associated with their efforts
(Strecher & Rosenstock, 1997). Therefore, expressed interest in utilizing preventative
services, such as BRCA1/2 genetic testing may be related to whether or not the perceived
benefits of this action outweigh the perceived risks.
Along with the original four items of the Health Belief Model, perceptions of selfefficacy, or belief in one’s ability to successfully navigate tasks and challenges, have
been proposed as an independent variable to partially explain interest in preventative
health behavior (Rosenstock et al., 1988). Individuals must not only feel that the benefits
of preventative action would outweigh the costs, but also feel that they are competent to
overcome perceived barriers to take action.

1.5 Rationale
The first objective of this study is to identify factors that predict women’s interest
in genetic testing for hereditary breast cancer syndromes. Previous literature suggests that
women thought to be at risk for breast cancer based on their family history may benefit
from pursuing genetic testing. Genetic counseling and subsequent testing for cancerpredisposing mutations is linked to increased screening behaviors, which help early
diagnosis and management of cancer if it does develop (Botkin et al., 2003). Genetic
testing may promote patient empowerment as some women report feeling more control
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over their health after deciding to pursue genetic testing (Gooding et al., 2005). Many
studies following the initial rise in commercialized genetic testing suggested that
education and perceived risk of developing breast cancer were the biggest predictors in
women’s reported interest in genetic testing services, despite ethnicity and income.
African American women and Hispanic women of low socioeconomic status have
reported high interest in learning more about cancer genetic testing (Komenka et al.,
2015).
However, literature has also shown that these services are primarily utilized by
women who have had more education, have greater annual household incomes, have
some form of health insurance, and are Caucasian (Lerman et al., 1996) Currently,
services are reported to be underutilized by ethnic or racial minorities and women with
lower socioeconomic statuses, despite the fact that hereditary breast cancer is no more or
less likely to affect these populations, and is more likely to be the cause of death if it does
develop either due to later diagnoses or more aggressive manifestations. The second goal
of this study will be to attempt to clarify whether or not services are underutilized by
these populations because they are unaware of these services or if the perceived utility of
genetic testing in these populations is not high enough to outweigh concerns related to
accessibility and psychological impact, or possibly a combination of the two.
The third goal of this study is to compare historical factors that predict interest in
genetic testing to those that are expressed in this study. Since the first utilization of
breast cancer genetic testing, many aspects of this process have changed. Legislation has
now made genetic testing more affordable by making it possible to be covered by public
insurance. Genetic information is now protected by law, potentially alleviating fears of
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discrimination and stigma. Celebrity use and publication of experiences with genetic
testing have increased awareness of services and aided in normalizing the process. These
factors together suggest that there may be differences in the way the general population
of women now perceives genetic testing than they might have in its early days. The
healthcare barriers and perceived disadvantages that women feel concerning genetic
testing in 2016 may be very different than those that were identified in the early 2000s.
Despite all that has changed since BRCA testing was first commercialized in 1996
to make this service more accessible to underserved populations, research suggests that
vulnerable and historically discriminated against populations still are not utilizing genetic
testing services at as great a frequency (Glenn, Chawla & Bastani, 2012). However, in
previous studies, women in these communities have expressed interest in these services.
This raises a question of what factors are specifically preventing women from seeking
genetic testing. Therefore, we hypothesize that while participants of all backgrounds will
express similar levels of interest in genetic testing services, women from underserved
populations will be more likely to cite concerns regarding accessibility and utility, and
less likely to agree with the proposed benefits of genetic testing.
1.51 Potential Risks
A potential concern of this study is that presenting the risk of breast cancer may
raise individual’s anxiety concerning their chance of having a hereditary cancer
syndrome. To address this, participants were provided with a fact sheet containing
instructions for contacting a local genetic counselor if they find themselves experiencing
increased anxiety about their personal risk of having a hereditary cancer syndrome
(Appendix A). Information gained from this study may not benefit the participants
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directly. However, the results of the study may benefit current and future patients with
hereditary breast cancer syndromes. Information gleaned from participants’ responses
will aide in developing educational tools and outreach strategies to better include
underserved populations.
1.6 Purpose
The current study explores the attitudes and beliefs of women across demographic
characteristics concerning genetic testing for hereditary breast cancer. The first goal of
this study is to identify factors that predict women’s interest in genetic testing for
hereditary breast cancer. The second goal of this study is to clarify women’s perceptions
of the personal and clinical utility of genetic testing for hereditary breast cancer. The
third goal of this study is to compare factors that predict interest in genetic testing for
hereditary breast cancer in this population against factors that have predicted interest in
previous studies. This study aims to provide insight into women’s perceived utility and
knowledge of genetic testing services. It also aims to identify populations that may
benefit from further education about hereditary breast cancer genetic testing services, as
well as what concepts and concerns educational outreach should address.
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CHAPTER II. ASSESSING WOMEN’S ATTITUDES TOWARDS GENETIC
TESTING FOR HEREDITARY BREAST CANCER1

1

Apostolico, T.J., Hill-Chapman, C.R., Heiney, S.P., & Murphy, R.T. To be submitted to
Journal of Community Health
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2.1 Abstract
OBJECTIVES: Hereditary Breast and Ovarian Cancer (HBOC) is an autosomal dominant
cancer predisposition syndrome with a 46-87% lifetime risk of breast cancer. Unaffected
women who have HBOC are eligible for more screening procedures and prophylactic
surgeries that may reduce the risk of developing cancer by up to 95%. The objectives of
this study were to assess women’s awareness of and interest in breast cancer genetic
testing services, as well as women’s attitudes and beliefs regarding the clinical utilization
of HBOC genetic testing across demographic categories. METHODS: Two-hundred and
sixty-eight women completed a 35-item survey designed to capture perceptions of HBOC
and genetic testing, attitudes towards genetic testing for HBOC, and demographics.
RESULTS: Two-hundred and eight women met participation criteria. One-hundred and
fifty-five (75%) indicated prior awareness of genetic testing services. One-hundred and
forty-three (69%) indicated interest in genetic testing for HBOC. Black women, women
with lower levels of education, and women with lower household incomes reported less
awareness, but similar levels of interest in genetic testing services when compared to
other participants. CONCLUSIONS: Women are interested in genetic testing for HBOC.
Specific counseling on barriers to minority and low socioeconomic communities, such as
cost and education regarding genetic testing procedures, may be beneficial in increasing
utilization of genetic testing for HBOC in these communities. Women who experience
more discrimination may have increased perceptions of their susceptibility to hereditary
cancer syndromes and may benefit from personalized risk counseling.
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2.2 Introduction
Hereditary Breast and Ovarian Cancer (HBOC) is an autosomal dominant cancer
predisposition syndrome caused by germline mutations in the breast cancer 1 (BRCA1)
and breast cancer 2 (BRCA2) tumor suppressor genes. Individuals who have a pathogenic
gene mutation in either BRCA1 or BRCA2 have a 46-87% life time risk of developing
breast cancer, compared to a general population risk of 12% (National Cancer Institute,
2016). A prophylactic bilateral mastectomy in mutation carriers has been found to reduce
the risk of breast cancer by at least 90% (Hartmann et al., 2001).
Women who are determined to have a high risk of developing breast cancer,
either by known genetic variant or family history, are eligible and encouraged to seek
high-risk screening procedures to decrease this risk (National Comprehensive Cancer
Network, 2016). These procedures, including earlier and more frequent utilization of
physical examinations and imaging techniques, have been shown to detect a larger
number of cases of breast cancer at an earlier stage of disease (DeSantis et al., 2013; Berg
et al., 2012). Women found to be at higher risk of developing breast cancer are also
offered the option of having a risk reducing prophylactic procedure, such as a
mastectomy, which may reduce the risk of breast cancer by as much as 90-95% (Rebbeck
et al., 2004).
Genetic testing for a hereditary breast cancer mutation has multiple proposed
benefits. Asymptomatic patients who learn they have a mutation that increases their risk
of developing breast cancer can begin to follow high-risk screening regimens to promote
early detection, and may consider risk reducing surgeries (Scheuer et al., 2002).
Receiving genetic counseling and testing, whether the result is positive or negative, has
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been shown to increase utilization of mammography and breast self-exams post result
disclosure (Botkin et al., 2003).
Historically, genetic testing services have been underutilized by individuals who
are minorities and individuals who are in lower socioeconomic classes (Glenn, Chawla,
& Bastani, 2012; Thompson et al., 2003). Women reporting higher levels of education
are more likely to report awareness and interest in genetic testing services (Lerman et al.,
1994). However, within the past decade the climate surrounding genetic testing has
shifted, potentially increasing not only the general population’s awareness of genetic
testing services but also their ability to access these services. Our study aimed to
determine women’s awareness of and interest in breast cancer genetic testing services, as
well as women’s attitudes and beliefs regarding the potential clinical and personal
utilization of genetic testing for HBOC across multiple demographic categories.

2.3 Materials and methods
2.3.1 Design and participants
Women, age 18 or older, who had not yet undergone genetic testing for hereditary
breast cancer syndromes in the United States were surveyed. Potential participants were
required to meet eligibility criteria in order to proceed with the questionnaire to confirm
that only the opinions of the targeted population would be captured by the study. Males
were excluded from this study as the cancer risks and medical management
recommendations differ significantly between male and female BRCA1/2 carriers.
Women who had already undergone genetic testing for hereditary cancer syndromes were
excluded from the study as their opinions concerning benefits and barriers would have
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already been informed by the testing and counseling process. Women who were not from
the United States were excluded as other countries not only differ in their guidelines and
recommendations, but also in their national health insurance programs. Individuals who
met exclusionary criteria were disqualified from participating in the questionnaire via the
skip logic function of the questionnaire programming software provided by
SurveyMonkey.com. Based upon G* power program, we determined that at a statistical
significance level of !=0.05, we would require 60 participants. The threshold for G*
power was exceeded for all statistical analyses.
Responses were collected from November 1st, 2016 to February 8th, 2017. In order
to capture a diverse sample, women were invited to participate through three channels:
Facebook.com, student classes, and homeless shelters. The invitation to participate can
be found in Appendix B. Individuals were invited to participate in the study through the
social network, Facebook.com. Students enrolled in Introductory Biology, Introductory
Chemistry, Introductory Nursing, and Introductory Psychology at a small public liberal
arts college in the southeastern United States were invited to participate in the study in
return for extra credit in their coursework. Individuals utilizing services provided by
shelters assisting those in need in South Carolina were also invited to participate verbally
in return for a $5 food coupon. Signed letters of support were obtained from directors of
any shelter that participated prior to the distribution of the questionnaire (Appendix C).
A flyer advertising the study and providing standardized background information on
hereditary cancer and genetic counseling was distributed to women at the shelter
(Appendix D). Women who expressed interest in completing the questionnaire sat in
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private with the principle investigator, who assisted the participants in reading the
background information and questionnaire, and documenting responses.
2.3.2 Instrument
An original questionnaire utilizing skip logic was developed through
SurveyMonkey.com. The questionnaire (Appendix E) was constructed by the principle
investigator and contained thirty-five quantitative items used to measure categorical
information from the participants. This measure was reviewed and edited by all members
of the committee for face validity. The questionnaire utilized a series of multiple choice
questions designed to assess the participant’s prior awareness of breast cancer genetic
testing services and interest in genetic testing for hereditary breast cancer. One
continuous item was utilized to elucidate participants’ perceptions of their cancer risk
(Gurmenkin Levy et al., 2006). Validated scales were utilized to ascertain participants’
perceived self-efficacy (Schwarzer & Jerusalem, 1995), perceptions of daily
discrimination (Krieger et al., 2005), and prior general knowledge regarding BRCA1/2
(Lerman et al., 1996). The questionnaire contained a version of the Health Belief Model
(HBM) modified specifically for this questionnaire to assess perceived susceptibility and
severity of hereditary breast cancer, and perceived benefits and barriers of preventive
genetic testing (Wang et al., 2007; Jacobsen et al., 1997).
Cronbach’s alpha scores were calculated for each scale. For the perceived selfefficacy scale, ! = 0.99. For the daily discrimination scale, ! = 0.71. For the perceived
susceptibility to hereditary breast cancer scale, ! = 0.80. For the perceived severity of a
hereditary breast cancer scale, ! = 0.84. For the proposed benefits scale, ! = 0.78, and
for the proposed risks and barriers scale, ! = 0.61 As the Cronbach’s alpha calculated
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for participants’ prior knowledge of hereditary breast cancer was ! < 0.50, these items
were not analyzed as a scale and instead analyzed separately.
Demographic information including age, gender, race, level of education,
relationship status, region of residence in the United States, number of children, annual
household income, and current method of health insurance was obtained. The survey
also contained questions specific to breast cancer, including personal and family histories
of breast cancer and genetic testing in order to better characterize whether or not the
participant would be considered at high risk of having a hereditary cancer syndrome. The
demographic and categorical data provided variables for statistical analysis.
Prior to beginning the questionnaire, all participants were provided with a brief
and succinct definition of hereditary breast cancer and genetic counseling (Appendix D).
Consent agreement was provided on the first page of the questionnaire in accordance
with the protocol approved by the University of South Carolina Institutional Review
Board.
2.3.3 Data Analysis
For quantitative data analysis, responses were compared as a whole, as well as
divided into groups for further investigation. Data analysis was performed using
Statistical Package for the Social Sciences, Version 24. One-way ANOVA tests
examined the statistical significance (p < 0.05) of associations between demographic
factors and levels of interest and awareness of genetic testing services. Spearman and
Pearson correlations were utilized to further explain associations between variables such
as age and education and awareness of and interest in genetic testing for hereditary breast
cancer.
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To analyze responses to the HBM, average ratings were calculated for each item
regarding perceptions of disease susceptibility and severity, and the benefits and barriers
of testing using the Likert scale format (strongly disagree = 1; disagree = 2; agree = 3;
strongly agree = 4). Mann-Whitney U tests were used to examine the statistical
significance of associations between reported awareness and interest in genetic testing
services and items of the HBM. Kruskal-Wallis H tests were used to examine the
statistical significance of associations between reported demographic factors and items of
the HBM.

2.4 Results
2.4.1 Demographic Information
Of the 268 responses to the four-item section of the questionnaire that determined
eligibility, 238 responses met criteria. Ineligible participants included men (n = 6),
minors (n = 4), individuals who had already had genetic testing for BRCA1/2 (n = 17),
and individuals who lived outside of the United States (n = 3). Of those who met criteria,
30 did not complete more than 80% of the survey and were excluded from data analysis,
resulting in a total of 208 eligible responses.
Of the 208 responses, 65% of participants described themselves as non-Hispanic
white (n = 135) and 26% of participants described themselves as black (n = 54). The
average age of participants was 34.11 with a range of 18 to 65 years of age and a standard
deviation of 14.86. The majority of participants reported receiving a Bachelor’s degree
or higher (n = 121). 64.4% of participants reported utilizing employer-provided health
insurance (n = 134). The majority of participants were single (n = 93), had no children (n
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= 119), and lived in the eastern region of the United States (n = 177). Participants had a
mode annual household income reported between $125,000 to $149,999 (n = 17).
Demographics of individual respondents are shown in Table 2.1
2.4.2 Awareness of Genetic Testing Services
The majority of participants (74.5%) indicated that prior to this survey they were
aware of genetic testing services for hereditary breast cancer. Statistical significance (p <
0.05) was noted in differences between average awareness of services within multiple
demographic factors, including race, highest level of education, health insurance
coverage, and annual household income. A demographic comparison of women who
reported awareness and those who did not can be found in Table 2.2.
Black women were statistically significantly less likely to have heard of genetic
testing for hereditary breast cancer than non-Hispanic white women (p = 0.03). Women
who reported utilizing government-provided health insurance were less likely to be aware
of services than women who reported utilizing employer provided private insurance (p <
0.01). Women who reported an annual household income of less than $10,000 were less
likely to be aware of services than women who reported an annual income of $200,000 or
more (p = 0.03).
Age had a weak but statistically significantly relationship to awareness of genetic
testing services (r = 0.23, p < 0.01). Younger women were less likely to be aware of
services than older women. Education also had a moderate but statistically significantly
correlation with awareness of testing services. Women who reported obtaining higher
levels of education were more likely to be aware of genetic testing services than those
who reported lower levels of education (r = 0.33, p < 0.01).
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Table 2.1 Participant demographic information
Individual Participant
Race
Asian
Black American
Hispanic
Non-Hispanic White
Highest Education
Less than high school
High school/GED
Some college
Associate’s degree
Bachelor’s degree
Graduate degree
Age
< 20 years
20 – 24 years
25 – 29 years
30 – 34 years
35 – 39 years
40 – 44 years
45 – 49 years
50 – 54 years
55 – 59 years
60 – 64 years
> 65 years

N=
208

(%)

Individual Participant

10
54
7
135

(4.9)
(26.2)
(3.4)
(65.5)

2
30
50
5
76
45
28
69
17
4
13
8
13
32
18
5
1

N=
208

(%)

Marital Status
Married
Divorced/Separated
Cohabitating
Single

82
7
26
93

(39.4)
(3.4)
(12.5)
(44.7)

(1.0)
(14.4)
(24.0)
(2.4)
(36.5)

No. of children
0 children
1 child
2 children
3 children
4 or more children

119
10
37
20
19

(57.2)
(4.8)
(17.8)
(9.6)
(9.2)

(21.6)

Income

(13.5)
(33.2)
(8.2)
(1.9)
(6.3)
(3.8)
(6.3)
(15.4)
(8.7)
(2.4)
(0.5)

< $10,000
$10,000 - $24,999
$25,000 - $49,999
$50,000 - $74,999
$75,000 - $99,999
$100,000 - $124,999
$125,000 - $149,999
$150,000 - $174,999
$175,000 - $199,999
> $200,000
Prefer not to answer
Residency

20
11
11
23
19
14
17
7
5
48
33

(9.6)
(5.3)
(5.3)
(11.1)
(9.1)
(6.7)
(8.2)
(3.4)
(2.4)
(23.1)
(15.9)

87
90
6
1
5
19

(41.8)
(43.3)
(2.9)
(0.5)
(2.4)
(9.1)

Insurance
Northeast2
Uninsured
9
(4.3)
Southeast3
University provided
16
(7.7)
Midwest4
1
Government provided
20
(10.6)
Northwest5
Self-provided private
28
(13.5)
Southwest6
Employer private
134
(64.4)
Did not specify
1
Includes Medicaid and Medicare
2
Includes ME, VT, NY, NH, MA, RI, CT, NJ, PA, DE, MD, DC
3
Includes VA, WV, KY, TN, NC, SC, GA, FL, MS, AL, Puerto Rico
4
Includes OH, IN, MI, IL, WI, MN
5
Includes WA, OR, ID, MT, AK, WY, CO
6
Includes TX, NM, AZ, NV, UT, CA, HI
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Table 2.2 Demographic comparison of aware versus unaware individuals
Aware Individuals
n = 155
(%)
Race
Asian
Black American
Hispanic
Non-Hispanic White
Highest Education
Less than high school
High school/GED
Some college
Associate’s degree
Bachelor’s degree
Graduate degree
Age
< 20 years
20 – 29 years
30 – 39 years
40 – 49 years
50 – 59 years
> 60 years
Income
< $10,000
$10,000 - $24,999
$25,000 - $49,999
$50,000 - $74,999
$75,000 - $99,999
$100,000 - $124,999
$125,000 - $149,999
$150,000 - $174,999
$175,000 - $199,999
> $200,000
Prefer not to answer
Health Insurance
Uninsured
University-provided
Government-provided1
Self-provided private
Employer-provided private
1
Includes Medicare and Medicaid

Unaware Individuals
n = 53
(%)

Group Total
N

9
32
6
107

(90.0)
(59.3)
(85.7)
(79.3)

1
22
1
28

(10.0)
(40.7)
(14.3)
(20.7)

10
54
7
135

1
14
32
4
64
40

(50.0)
(46.7)
(64.0)
(80.0)
(84.2)
(88.9)

1
16
18
1
12
5

(50.0)
(53.3)
(36.0)
(20.0)
(15.8)
(11.1)

2
30
50
5
76
45

15
59
16
16
43
6

(53.6)
(68.6)
(94.1)
(76.2)
(86.0)
(100.0)

13
27
1
5
7
0

(46.4)
(31.4)
(5.9)
(23.8)
(14.0)
(0.0)

28
86
17
21
50
6

9
8
8
13
14
13
13
5
4
41
27

(45.0)
(72.7)
(72.7)
(56.5)
(73.7)
(92.9)
(76.5)
(71.4)
(80.0)
(85.4)
(81.8)

11
3
3
10
5
1
4
2
1
7
6

(55.0)
(27.3)
(27.3)
(43.5)
(26.3)
(7.1)
(23.5)
(28.6)
(20.0)
(14.6)
(18.2)

20
11
11
23
19
14
17
7
5
48
33

6
10
8
20
110

(66.7)
(62.5)
(40.0)
(71.4)
(82.1)

3
6
12
8
24

(33.3)
(37.5)
(60.0)
(38.6)
(17.9)

9
16
20
28
134
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2.4.3 Interest in Genetic Testing for Hereditary Breast Cancer
The majority of participants (68.75%) indicated they would be interested in
pursuing genetic testing for hereditary breast cancer. One-way ANOVAs showed
statistical significance (p < 0.05) between reported average interest within multiple
demographic factors, including marital status and number of children. Married woman
were statistically significantly less likely to report interest in testing than woman who had
never been married (p < 0.01). Women who reported having no children were statistically
significantly more likely to report interest in genetic testing for hereditary breast cancer
than those who reported having 2 or more children (p < 0.01). Race did not have a
statistically significantly association with interest in testing. However, a considerable
trend towards significance was noted in that black women tended to be more likely to
report interest in testing than non-Hispanic white women (p = 0.051).
Age had a moderate but statistically significantly relationship with interest in
testing services (r = -0.32, p = 0.01), with younger women more frequently expressing
interest in genetic testing for hereditary breast cancer. Highest level of education was
found to have a weak but statistically significantly correlation with interest (r = -0.17, p =
0.01), with women who reported obtaining higher levels of education less frequently
reporting interest than other participants. Women’s perceptions of their risk of
developing breast cancer was not statistically significantly associated with interest in
genetic testing.
Women who reported interest in genetic testing were statistically significantly
more likely to perceive themselves to be at risk for a genetic mutation that would
predispose them to breast cancer (p < 0.01). Interested participants were also more likely
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to agree or strongly agree with the proposed benefits of genetic testing than those who
were not interested (p < 0.01). Interested participants reported statistically significantly
higher frequencies of day to day discrimination (p < 0.01). Prior awareness of testing
services was not found to be statistically significantly associated with interest. There was
no statistically significant difference between interested participants and uninterested
participants concerning perceptions of the severity of a genetic predisposition to cancer,
overall perceptions of barriers to genetic testing, perceptions of self-efficacy, and general
knowledge of hereditary breast cancer. A comparison of the demographics of interested
and uninterested participants can be found in Table 2.3.
2.4.4 Health beliefs
Table 2.4 represents 20 items that were derived from the HBM. The data was
generated by the Likert scale rating format to determine individual perceptions of the
susceptibility to and the severity of a genetic mutation that would increase their risk of
breast cancer, as well as the benefits and barriers of preventative testing for BRCA1/2
pathogenic variants. A high average is associated with agreement (strongly agree = 4) to
a statement, whereas a low average is associated with disagreement (strongly disagree =
1). Items were compared among demographic groups, analyzed, and averaged.
In general, women reported high agreement to the proposed benefits of genetic
testing and low agreement to the proposed barriers of genetic testing (Figures 2.1 & 2.2).
The most strongly agreed with benefits included learning about their children’s risk for
breast cancer, informing action regarding dealing with cancer risk, and helping other
family members decide whether to test. Women disagreed most strongly with the
proposed barriers that their family would not be supportive, testing would not cause them
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Table 2.3 Demographic comparison of interested versus uninterested individuals
Interested Individuals
n = 143
(%)
Race
Asian
Black American
Hispanic
Non-Hispanic White
Highest Education
Less than high school
High school/GED
Some college
Associate’s degree
Bachelor’s degree
Graduate degree
Age
< 20 years
20 – 29 years
30 – 39 years
40 – 49 years
50 – 59 years
> 60 years
Income
< $10,000
$10,000 - $24,999
$25,000 - $49,999
$50,000 - $74,999
$75,000 - $99,999
$100,000 - $124,999
$125,000 - $149,999
$150,000 - $174,999
$175,000 - $199,999
> $200,000
Prefer not to answer
Health Insurance
Uninsured
University-provided
Government-provided1
Self-provided private
Employer-provided private
1

Uninterested Individuals
n = 65
(%)

Group Total
N

6
45
5
86

(60.0)
(83.3)
(71.4)
(63.7)

4
9
2
49

(40.)
(16.7)
(28.6)
(36.3)

10
54
7
135

2
21
43
4
46
27

(100.0)
(70.0)
(86.0)
(80.0)
(60.5)
(60.0)

0
9
7
1
30
18

(0.0)
(30.0)
(14.0)
(20.0)
(39.5)
(40.0)

2
30
50
5
76
45

20
73
13
11
23
3

(71.4)
(84.9)
(76.5)
(52.4)
(46.0)
(50.0)

8
13
4
10
27
3

(28.6)
(15.1)
(24.5)
(47.6)
(54.0)
(50.0)

28
86
17
21
50
6

14
8
7
18
15
9
11
6
3
26
26

(70.0)
(72.7)
(63.7)
(78.3))
(78.9)
(64.3)
(64.7)
(85.7)
(60.0)
(54.2)
(78.8)

6
3
4
5
4
5
6
1
2
22
7

(30.0)
(27.3)
(36.4)
(21.7)
(21.1)
(35.7)
(35.3)
(14.3)
(40.0)
(45.8)
(21.2)

20
11
11
23
19
14
17
7
5
48
33

8
11
14
19
90

(88.9)
(68.7)
(70.0)
(67.9)
(67.2)

1
5
6
9
44

(11.1)
(31.3)
(30.0)
(32.1)
(32.8)

9
16
20
28
134

Includes Medicare and Medicaid
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Table 2.4 Health Belief Model and comparison of groups
All
Participants
N = 208

Aware
Individuals
n = 155

Unaware
Individuals
n = 53

Interested
Individuals
n = 143

Uninterested
Individuals
n = 65

p

2.0944

2.13635

1.9519

2.2183

1.8047

<0.01

2.8476

2.8538

2.8302

2.8718

2.7949

Learn about children’s risk for breast cancer

3.1990

3.1623

3.3077

3.2676

3.0469

0.02

Help other family members decided whether to test

3.0386

3.0260

3.0755

3.1469

2.7969

<0.01

Ease my mind, regardless of test result

2.5865

2.5290

2.7547

2.6993

2.3385

<0.01

Inform action regarding dealing with cancer risk

3.1463

3.1307

3.1923

3.2746

2.8571

<0.01

Help me reduce uncertainty about the future

2.7902

2.7647

2.8654

2.9149

2.5156

<0.01

Help me make important life decisions

2.5099

2.4901

2.5686

2.6170

2.2623

<0.01

Provide a sense of personal control

2.9565

2.9481

2.9811

3.0563

2.7385

<0.01

May not be able to cope with the result

2.1359

2.1176

2.1887

2.1408

2.1250

Do not understand what will be done

1.9275

1.8701

2.0943

2.0350

1.6875

<0.01

Would not do anything different to manage cancer risk

1.8019

1.8247

1.7358

1.7203

1.9844

<0.01

Would have a negative impact on family

1.8641

1.8824

1.8113

1.8028

2.0000

0.03

Cannot afford the cost

2.4975

2.4342

2.6863

2.5929

2.2857

0.02

Family would not be supportive

1.5700

1.5649

1.5849

1.5664

1.5781

Testing may lead to discrimination

1.9712

2.0129

1.8491

1.9371

2.0462

Testing would not provide new information

1.8317

1.8710

1.7170

1.7622

1.9846

Perceptions of susceptibility
Perceptions of severity
Benefits

p
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Barriers

Statistically significant differences between groups appear in bold type, p < 0.05

0.03

Learn about children’s risk for breast cancer
Inform action regarding dealing with cancer risk
Help other family members decided whether to test
Provide a sense of personal control
Help me reduce uncertainty about the future
Ease my mind, regardless of test result
Help me make important life decisions
0

0.5

1

1.5

2

2.5

3

3.5

2.5

3

Figure 2.1 Agreement with benefits of genetic testing

Cannot afford the cost
May not be able to cope with results
Testing may lead to discrimination
Do not understand what will be done
Would have a negative impact on family
Testing would not provide new information
Would not do anything different to manage cancer risk
Family would not be supportive
0

0.5

Figure 2.2 Agreement with barriers of genetic testing
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to do anything different to manage their cancer risk, and testing would not provide new
information. Women only agreed with one proposed barrier, that they would not be able
to afford the cost of testing.
Interest strongly influenced women’s perceptions of susceptibility, benefits, and
barriers to genetic testing for hereditary cancer (Table 2.4). Women who were interested
in testing were more likely to perceive themselves as susceptible to a genetic mutation
that would predispose them to breast cancer (p < 0.01). Interested participants agreed
more strongly with all proposed benefits to genetic testing (p < 0.01). Interested women
statistically significantly agreed more with the statement “I am afraid to undergo genetic
testing because I do not understand what will be done” (p < 0.01), and the statement “I
cannot afford the cost of genetic testing” (p = 0.02). Women who were not interested in
testing agreed statistically significantly more than interested women with a few barriers
to genetic testing, including the statements, “Genetic testing will not help me because I
would not do anything different to manage cancer risk” (p < 0.01), “Genetic testing will
have a negative impact on my family” (p = 0.03), and “Genetic testing will not tell me
anything new about my risk I do not already know” (p = 0.03). Interest had no
statistically significant effect on women’s reports of perceptions of the impact a
hereditary breast cancer syndrome would have on their lives or women’s reports of selfefficacy.
Age played a role in influencing women’s perceptions of the benefits and barriers
to genetic testing. Younger women were more likely to agree with the statement,
“Genetic testing will help me make important life decisions” (p = 0.02). They more
strongly agreed with a few barriers, including “I am afraid to undergo genetic testing
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because I may not be able to cope with the result” (p < 0.01), “I am afraid to undergo
genetic testing because I do not understand what will be done” (p < 0.01), and “I cannot
afford the cost of genetic testing” (p < 0.01).
There were statistically significant differences in the benefits and barriers women
most strongly agreed with between different racial groups (Figures 2.3 & 2.4). Black
women were statistically significantly more likely (p < 0.01) to agree with the statement
“Genetic testing will help me make important life decisions” than non-Hispanic white
women. In terms of barriers, black women were more likely to agree with the statements,
“I am afraid to undergo genetic testing because I may not be able to cope with the
results” (p = 0.02), “I am afraid to undergo testing because I do not understand what will
be done” (p < 0.01), and “I cannot afford the cost of genetic testing” (p < 0.01) than nonHispanic white women. Asian women were statistically significantly more likely to
agree with the statement “Genetic testing will not help me because I would not do
anything different to manage my cancer risk” (p = 0.01) than Hispanic women.
Highest level of education influenced women’s perceptions of the benefits and
barriers to genetic testing for hereditary cancer. Women who reported receiving less than
a bachelor degree were more likely to agree with the statement, “Genetic testing will help
me make important life decisions” (p < 0.01) than those that reported receiving a
bachelor’s degree. Women who reported receiving less than a bachelor degree were also
more likely to agree with the statements “I am afraid to undergo genetic testing because I
may not be able to cope with the results” (p = 0.03), “I am afraid to undergo genetic
testing because I do not understand what will be done” (p < 0.01), and “I cannot afford
the cost of genetic testing” (p = 0.01).
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Learn about children's risk for breast cancer

Inform action regarding dealing with cancer risk

Help other family members decide whether to test

Provide a sense of personal control

Help me reduce uncertainty about the future

Ease my mind, regardless of test result

Help me make important life decisions
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Figure 2.3 Race vs. agreement with benefits
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Figure 2.4 Race vs. agreement with barriers
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Marital status was similarly associated with perceptions of benefits and barriers
regarding genetic testing for hereditary breast cancer. Women who reported never being
married were statistically significantly more likely to agree with the statements, “Genetic
testing will help me make important life decisions” (p < 0.01), “I am afraid to undergo
genetic testing because I may not be able to cope with the result” (p < 0.01), “I am afraid
to undergo genetic testing because I do not understand what will be done” (p < 0.01), and
“I cannot afford the cost for genetic testing” (p < 0.01) than women who reported that
they were married.
Women who reported having no children were more likely to agree with the
statements, “Genetic testing will help me make important life decisions” (p < 0.01). “I am
afraid to undergo genetic testing because I may not be able to cope with the result” (p <
0.01), “I am afraid to undergo genetic testing because I do not understand what will be
done” (p < 0.01), and “I cannot afford the cost for genetic testing” (p < 0.01) than women
who reported having two or more children. Women who reported having one child
trended to being less likely to agree with the statement, “Genetic testing to learn my risk
will help other family members decide whether to undergo testing” (p = 0.04) than
women who reported having no children or more than one child.
Participant’s reported insurance was only statistically significantly associated with
increased agreement with barriers to genetic testing. Participants who reported utilizing
government provided health insurance were more likely to agree with the statements “I
am afraid to undergo genetic testing because I may not be able to cope with the results”
(p < 0.01) than those that reported utilizing employer-provided health insurance. These
participants were also more likely to agree with the statement, “I am afraid to undergo
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genetic testing because I do not understand what will be done” (p < 0.01) than
participants reporting utilization of university-provided health insurance or employer
provided health insurance. Participants who reported that they were currently uninsured
or utilizing university-provided health insurance were statistically significantly more
likely to agree with the statement, “I cannot afford the cost of genetic testing” (p < 0.01).
Participants who reported utilizing employer-provided or self-provided private insurance
more strongly agreed with the statement, “Genetic testing will not tell me anything new
about my risk I do not already know” (p = 0.01) than those who reported utilizing
university-provided health insurance.
Annual household income was also only statistically significantly associated with
increased agreement with barriers to genetic testing. Participants who reported annual
household incomes of less than $10,000 were statistically significantly more likely to
agree or strongly agree with the statement “I am afraid to undergo genetic testing because
I do not understand what will be done” (p < 0.01) than participants who reported annual
household incomes of greater than $200,000. Participants who reported annual household
incomes of less than $125,000 were statistically significantly more likely to agree with
the statement, “I cannot afford the cost for genetic testing” (p < 0.01) than participants
who reported annual incomes of greater than $200,000.
2.4.5 Discrimination
We examined our hypothesis that interest in genetic counseling would be lower
for those who have higher reports of perceived discrimination. Unexpectedly,
participants who reported higher frequencies of daily discrimination also reported greater
interest in genetic testing. To investigate our findings further, we examined the potential
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mediating role of perceived susceptibility of a having inherited a genetic mutation that
would predispose one to cancer between the relationship of perceived discrimination and
interest in genetic counseling. Although current perspectives on mediation propose that
the requirements outlined by Baron and Kenny (1986) are unnecessary (Shrout & Bolger,
2002), relations between our study variables did meet the expectations. Both the
predictor, perceived discrimination, and the mediator, perceived susceptibility, were
related to the outcome variable, genetic testing interest (Table 2.5). We present our
findings in the conventional Baron and Kenny format for ease of interpretation.
Table 2.5 Correlations between perceived discrimination, perceived susceptibility,
and interest in genetic testing
1.
-

Perceived Susceptibility
Interest in Genetic Counseling
Perceived Discrimination

2.
.258**
-

3.
.173*
.244**
-

* Indicates p<0.05
** Indicates p<0.01

Using a multiple logistic regression, we regressed the criterion variable of interest
in genetic testing on perceived discrimination in Step 1. In Step 2, we regressed interest
in genetic testing on both the predictor of perceived discrimination and on the proposed
mediator of perceived susceptibility and saw a reduction in the strength of perceived
discrimination to predict interest in genetic counseling. The third regression equation
provided an estimate of path c’, the relationship between perceived discrimination and
interest in genetic counseling, controlling for perceived susceptibility. When path c’ is
zero, there is evidence of complete mediation. Path c’ was found to be reduced, and no
longer statistically significant, suggesting partial mediation. The R2adj = .05 for the final
analysis indicated that almost 5% of the variability in interest in genetic counseling could
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be accounted for by the mediation of perceived discrimination by perceived
susceptibility.
We used the Sobel test to test the statistical significance of the mediating effect
and to determine whether the change from path c to path c’ of the standardized regression
coefficients was statistically significant. The statistically significant decrease (Sobel tests
= 2.24, p = .03) verified that perceived susceptibility partially mediated the relationship
between perceived discrimination and interest in genetic testing. A graphic representation
of this effect can be found in Figure 2.5

Figure 2.5 Mediating role of perceived susceptibility in the relationship between
perceived discrimination and interest in genetic testing
2.4.6 BRCA1/2 Knowledge
In general, women in this study scored high on all measures of knowledge of
BRCA1/2. For 5 of the 6 items, greater than or equal to 77% of women were able to
correctly identify true or false statements. However, only 53% of participants were able
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to correctly identify the statement, “The BRCA gene causes about one half of all breast
cancers” as “False”.

2.5 Discussion
The purpose of this study was to assess women’s interest in and attitudes towards
genetic testing for hereditary breast cancer across multiple demographic factors. The
main goals of the study were to identify factors that predict women’s interest in testing
and to clarify women’s perceptions of the utility of testing through the use of a Health
Belief Model (HBM). Given the rapidly evolving attitudes towards and increasing
accessibility to genetic testing, potential consumers’ thoughts regarding this service are
especially pertinent.
Previous studies have shown that genetic testing services are primarily utilized by
Caucasian women with private health insurance, and higher levels of education and
income. Minorities are less likely to be aware of the genetic testing services available to
them (Glenn, Chawla, & Bastani, 2012). Minority women have previously cited barriers
to testing such as accessibility, language barriers, and distrust in the medical community
(Glenn, Chawla, & Bastani, 2012; Thompson et al., 2003).
2.5.1 Awareness of Genetic Testing Services
The results of this study suggest the majority of women are aware of genetic
testing services. Our study noted statistically significant differences in frequency of
awareness between multiple demographic categories. Among our participants, black
women, women who had lower levels of education, and women with lower annual
incomes were all less aware of hereditary breast cancer genetic testing. These results
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support the findings of previous studies, and indicate that further outreach in low
socioeconomic communities by genetics professionals may be beneficial in reducing
disparities among consumers (Komenaka et al., 2015; Mai et al., 2014).
2.5.2 Interest in Genetic Testing for Hereditary Breast Cancer
Over half of our participants expressed interest in utilizing genetic testing for
hereditary breast cancer syndromes. There were statistically significant differences
between the women who reported interest and those who did not. Some of these
differences appear to stem from family unit demographics. Single women were more
likely than married women to report interest, and women with no children were more
likely to report interest in testing than women with 2 or more children. This observation
adds support to previous findings suggesting women who perceive themselves to have
stronger social supports are more likely to postpone genetic testing (Hesse-Biber & An,
2016).
Age had a statistically significant relationship with interest in testing. Consistent
with previous findings, younger women were more likely to express interest in genetic
testing for hereditary breast cancer than older women in our sample. As patient
populations age, they have been found to have decreased interest in medical information
seeking (Turk-Charles, Meyerowitz, & Gatz, 1997). Alternatively, younger women’s
increased interest in testing may be attributable to more exposure or education on genetic
testing in their formal schooling, or an acknowledgement of the approaching midlife
years and the increased risk of cancer that accompanies them (Sanderson et al., 2004;
Bottorff et al., 2002).

41

Women who reported receiving lower levels of education were more likely to
report interest in testing services than those who reported higher levels of education
Women who have higher levels of education may have more access and knowledge
regarding genetic technology and may be more aware of the limitations and indications
for genetic testing than those who have received lower levels of education (Sanderson et
al., 2004).
Notably, no statistically significant relationship between prior awareness of
testing services and interest in testing services was observed. Selected populations that
reported less awareness of services, such as black women and women with lower annual
incomes, did not have a statistically significant difference in their reported interest when
compared to other participants. However, black women did trend towards significance in
being more likely to report interest than non-Hispanic white women.
2.5.3 Health Belief Model
In this study, the Health Belief Model (HBM) provided a framework to better
understand women’s perceptions regarding the utility, benefits, barriers, and risks of
genetic testing for hereditary breast cancer. The HBM was used to not only examine
women’s perceptions as a whole, but also women’s perceptions within demographic
categories in order to help clarify differing attitudes towards genetic testing for hereditary
breast cancer.
Overall, participants expressed a positive attitude towards genetic testing for
hereditary breast cancer syndromes. On average, women agreed with all of the proposed
benefits to testing and disagreed with the majority of proposed barriers. Women agreed
most strongly with the proposed benefits that genetic testing would help them learn about
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their children’s risk for breast cancer, help inform action regarding dealing with cancer
risk, and help other family members make testing decisions. These benefits all confer
alterations to the personal health management of the participant and their family
members, and indicate that women are aware of and appreciate the clinical utility of this
testing.
As a whole, women in this study only agreed with one proposed barrier to genetic
testing for hereditary breast cancer syndromes. Participants were more likely to cite
agreement with the statement that they would not be able to afford the cost of testing,
suggesting that the perceived financial burden of genetic testing is a deterrent to women’s
decisions to pursue testing. Current billing procedures for genetic testing for hereditary
cancer syndromes are complex and vary based on indication, insurance plan, and the
laboratory chosen to complete the testing. The cost of genetic testing for hereditary
cancer billed to insurance may vary from $1,500 to $5,000, but if the patient is
determined to be an appropriate candidate for testing, out of pocket expenses are
anticipated to be much lower at approximately $100 (Invitae, 2017; Myriad Genetics,
2017). Currently, many laboratories offer financial assistance programs for underinsured
patients determined to be appropriate candidates for testing that can reduce the out of
pocket cost to less than $100 or waive the out of pocket cost completely.(Invitae, 2017;
Myriad Genetics, 2017). Education prior to the genetic counseling appointment regarding
the average anticipated cost of testing may help encourage women who believe this
service is not financially attainable to pursue genetic counseling when indicated.
Reported interest in testing was found to be statistically significantly associated
with women’s perceptions of their personal risk of having a genetic mutation that would
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increase the risk of having breast cancer. Perceptions of severity were not significantly
different between interested and uninterested women. Stronger agreement with all of the
proposed benefits of genetic testing was statistically significantly associated with interest,
suggesting that women who are interested in testing are also more likely to perceive there
to be clinical and personal utility in testing than those who are not.
Women who did not report interest in genetic testing statistically significantly
agreed more with three of the proposed barriers and risks. Uninterested women were
more likely to believe that testing would not affect their decisions regarding the
management of cancer risk and would not provide new information about their cancer
risk. Both of these barriers relate to clinical utility and may indicate that women who are
not interested in testing are less likely to perceive testing would provide personal health
gain. The last barrier that uninterested women agreed statistically significantly more with
was that testing would have a negative impact on their families. Given that the women in
our sample who most frequently reported disinterest in testing were those who were
married with more than one child, it is possible that this finding may be partially
explained by appreciation for the significance a positive result would have on offspring.
There were statistically significant differences in our sample regarding attitudes
and beliefs of racial groups towards genetic testing for hereditary breast cancer. Black
women were statistically significantly less likely to be aware of testing services,
indicating that they may be receiving less exposure and education on genetic testing
services than other races. Interestingly, black women trended towards expressing
significantly more interest in testing services than non-Hispanic white women. These
findings may suggest that a contributory factor towards the lower frequencies of minority
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women utilizing genetic testing services is lack of knowledge of and access to these
services, as opposed to a lack of appreciation of the potential utility of these services.
Black women were statistically significantly more likely to agree with three
barriers or risks to genetic testing than non-Hispanic white women. Black women were
significantly more likely to agree that they were afraid to undergo genetic testing because
they did not understand what would be done, and that they could not afford the cost of
testing. Both of these barriers cite educational and accessibility concerns that may be
aided by counseling and outreach.
Black women were also more likely to agree with the statement that they would
not be able to cope with the results of genetic testing. Previous studies have revealed a
complex relationship between fear of cancer and use of screening services. Women who
perceive themselves to be mildly or severely at risk of cancer are less likely to utilize
mammography than women who perceive themselves to be at moderate risk (Andersen et
al., 2003). The underuse of mammography in black women has been hypothesized to be
partially influenced by enhanced perceptions of breast cancer fatalism. In a qualitative
study, African American women described coping strategies such as denial and
repression to deal with fear of death due to breast cancer that caused them to avoid
preventative care, such as breast cancer screening (Peek, Sayad, & Markwardt, 2008).
Prior studies have also noted that women who report more intense emotional
representations of hereditary cancer and difficulty understanding hereditary cancer are
more likely to report difficulty coping with hereditary cancer testing (Voorwinden &
Jaspers, 2015). It is possible a contributory factor to black women’s underuse of genetic
testing services is related to an underlying fear of breast cancer diagnosis and an
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enhanced perspective of the probability of death due to breast cancer. Genetic counselors
should be aware that these patients may benefit psychosocially as they adjust emotionally
throughout the testing process from counseling addressing the effectiveness of treatment
for breast cancer when medical care is proactively sought.
In our study, socioeconomic status was found to be associated with more
agreement with perceived barriers to genetic testing. Education, health insurance
coverage, and annual household income all statistically significantly influenced women’s
attitudes towards genetic testing for hereditary breast cancer. Women were more likely
to agree that they would not be able to afford the cost of genetic testing if they had
received less than a bachelor’s degree, if they were currently uninsured or utilizing
university-provided health insurance, or if they reported a household income of less than
$125,000. The financial burden of genetic testing is a significant concern for women in
lower socioeconomic classes that may be aided by education on patient assistance
programs and financial aid counseling. Women who reported receiving less than a
bachelor degree, government-provided insurance, and a household income of less than
$10,000 were all more likely to agree that they were afraid to undergo genetic testing
because they did not understand what would be done. Education in low socioeconomic
communities should include an exploration of the agenda of a genetic counseling session
and the subsequent testing process.
2.5.4 Discrimination
Previous studies consistently note the significance of historical discrimination and
residual distrust in the medical community as a barrier to genetic testing in minority
women (Kennedy, Mathis, & Woods, 2007; Glenn, Chawla, & Bastani, 2012). The
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participants in our study did not statistically significantly differ in their reports of
discrimination between racial groups or socioeconomic factors. Our results indicated a
statistically significant relationship between reported interest in testing and increased
frequency of daily events of discrimination. Further analysis revealed a confounding
relationship between interest and discrimination that was partially explained by
perceptions of susceptibility to a cancer predisposing mutation. Women who reported
higher perceptions of susceptibility to a mutation not only significantly scored higher on
the daily discrimination scale, but also reported significantly more interest in testing.
This relationship indicates that women who experience more discrimination may perceive
themselves to be more susceptible to a mutation that would increase their risk of breast
cancer.
Previous studies have linked discrimination to many adverse physical and mental
health outcomes (Pascoe & Richman, 2009). To our knowledge, this is the first study to
show a relationship between discrimination and increased perceptions of susceptibility to
a genetic syndrome. Discrimination has the potential to be a source of chronic stress that
may accumulate to have significant effects on long-term health. Beyond the impact stress
may have on health, distress and anxiety have been associated with overestimations of
cancer risk (Tilburt, et al., 2011). Our findings indicate that those who experience
discrimination may be at greater risk of anxiety inflating their perceptions of their risk of
having a genetic mutation that would cause an increased risk of cancer.
2.5.5 BRCA1/2 Knowledge
Overall, the women in our sample scored high on the knowledge portion of the
questionnaire. Of note, one item, “The BRCA gene causes about one half of all breast
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cancers” (False), was answered incorrectly by almost half of the sample. As BRCA
mutations account for approximately 5% of all breast cancer cases, women in this study
had inflated perceptions of the frequency of BRCA related cancers. Women may benefit
from education and counseling from their healthcare providers regarding the frequency of
genetic cancers.
2.5.6 Practice Implications
Previous studies have noted the underuse of preventative genetic testing for
hereditary breast cancer in minority women. This study revealed that black women tend
to be less aware of genetic testing services, but equally as interested as their peers in
receiving them, indicating that lack of knowledge and accessibility are key contributory
factors to this underutilization as opposed to a lack of appreciation of the potential utility
of genetic testing for hereditary breast cancer. Similarly, women of lower socioeconomic
status, who reported lower household incomes, levels of education, and government
provided health insurance, were more likely to be unaware of services than their peers but
no less interested. Increasing exposure to genetic testing services in underserved
populations is possible, but may require the aid of multiple health care providers.
Mobile mammography has been shown to be an effective method at increasing
breast cancer screening in underserved communities and offering a channel of access to
women who have barriers to the medical community (Chen et al., 2016; Brooks et al.,
2013; Massin-Short et al., 2010). Given that our participants from these communities
expressed equal interest in genetic testing, despite less awareness, our findings support
the inclusion of a genetic counselor or genetics-trained health provider on a mobile
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mammography unit to speak with interested or high-risk women as a strategy to allow for
more education and exposure to genetic testing in these populations.
A novel relationship between increased experiences of discrimination and
increased perceptions of susceptibility to a genetic mutation that would increase breast
cancer risk was noted in our participants. Prior studies have indicated that women who
feel more discrimination are less likely to utilize health services (Pascoe & Richman,
2009; Andersen et al., 2003). While it may be more difficult to reach women who feel
more discrimination, they may benefit significantly from counseling and education
regarding risk estimates and strategies to decrease the risk of cancer.
As stated previously, historically, minorities, women who have non-private health
insurance, and women in lower socioeconomic classes are among the least likely to
pursue genetic testing services. In our study, black women, women with governmentprovided health insurance, women with lower annual household incomes, and women
with less formal education all consistently agreed statistically significantly more with one
barrier to testing, “I am afraid to undergo genetic testing because I do not understand
what will be done”. Unlike many of the potential barriers proposed in this study, this is a
patient concern genetic counselors and other health professionals are equipped to directly
address and impact.
Genetic counselors providing cancer-based genetic testing services should be
aware that minority women and women with lower socioeconomic status may arrive to a
genetics appointment with different concerns than other patients. Beyond contracting
with the patient, specifically addressing the procedural and logistical aspects of the
genetic testing process early in the appointment may aide in reducing perceived barriers
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to these patients. Although unconventional, touching on the testing process and
anticipated cost of testing prior to or in the beginning of the appointment may allow
women less comfortable in a medical setting to better focus on the genetic information
and education portions of the session later on if their concerns are adequately addressed
from the start. Additionally, information and educational materials designed for women
in underserved communities should specifically address the procedural and financial
aspects of genetic testing.

2.6 Limitations and Future Studies
One of the goals of this study was to capture the perspectives of a diverse
population. In order to do so, a number of self-selecting sampling methods were utilized,
which created potential self-selection bias. Women who chose to participate in this study
may have had stronger beliefs and attitudes towards genetic testing than women who did
not.
While the sample collected was diverse in terms of education, income, age, and
family unit characteristics, 85% of participants reported residing in the eastern region of
the United States. Future studies may wish to explore differences in attitudes across the
United States. Black women were well represented in the study, but the perspectives of
women of other minority groups were less represented. These results are not
generalizable to women of all minority backgrounds.
Information regarding HBOC and genetic testing was provided in a summary to
the participants. It is not clear if participants fully understood the summery, as the item
used to assess knowledge of BRCA1/2 most frequently incorrectly answered by
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participants was addressed in the summery. This may exemplify the complex nature of
explaining genetic predispositions by written material alone. We did not determine how
participants received information regarding genetic testing and HBOC. Learning which
sources women use to learn about genetic testing and hereditary cancer risk may have
provided revealing information.
While the HBM provided an abstract framework for exploring women’s
perceptions and attitudes towards genetic testing, further clarification through qualitative
data would have aided in the interpretation of results. A significant observation that was
noted in this study was women’s agreement that the cost of testing was perceived as a
barrier. Participants were not asked specifically what they believed the cost of testing to
be. Future studies should explore women’s concrete perceptions of the potential financial
burden of genetic testing to form a more accurate picture of this significant barrier.
This study focused specifically on the breast cancer risks of HBOC. In reality,
women with BRCA1/2 mutations are at increased risk for multiple cancers, including
ovarian and pancreatic cancer. It is possible that knowledge of these cancers risks may
have an impact on participants’ interest in and attitudes towards genetic testing for
BRCA1/2 that was not measured in this study.
A relationship between women’s reports of discrimination, increased interest in
testing, and increased perceptions of susceptibility to the inheritance of a genetic
mutation that would increase breast cancer risk was noted. To our knowledge, this is the
first study to demonstrate this relationship. It would be interesting to explore if this
relationship is present in other adult-onset conditions that are moderated by both genetic
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risk and environmental risk factors like stress and anxiety, such as Alzheimer’s disease or
heart disease.
The results of this study support intervention and outreach, potentially through
mobile mammography or mobile health units, in underserved communities to provide
education on genetic testing. Future studies should examine the effectiveness of such
interventions in the appropriate utilization of genetic testing services in underserved
communities, as well as the effectiveness of altering the genetic counseling agenda to
address issues such as expected out of pocket costs and the testing procedure prior to the
genetic counseling session through handout or phone call, or in the beginning of the
genetic counseling session.

2.7 Summary
In recent years, genetic testing for hereditary cancer syndromes has not only
become more accessible to the general population, but also received more media attention
and exposure, increasing the general public’s awareness of this medical service. Genetic
testing offers many potential benefits, including earlier and more frequent screening to
prevent advanced stages of cancer, and the provision of personalized risk information to
family members. Given the rapidly evolving attitudes towards and increasing
accessibility to genetic testing, potential consumers’ thoughts regarding this service are
especially pertinent.
Our findings indicate that the majority of women are aware of and interested in
genetic testing for hereditary breast cancer syndromes, and perceive there to be clinical
and personal utility in testing, across demographic categories.
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We noted statistically significant differences in the concerns and barriers to
genetic testing cited by black women and women of lower socioeconomic status when
compared to other participants. We suggest that genetic counselors providing services to
these women are especially cognizant of the potential concerns of cost and lack of
awareness of what genetic testing entails expressed by these populations, and consider
addressing these concerns prior to or earlier in the genetic counseling session to ensure
these patients are able to focus on the education provided without the distraction of these
potential barriers. Future studies are necessary to determine the effectiveness of this
proposal.
We observed a relationship between participants reports of increased frequency
of discrimination and increased interest in genetic testing that was partially modified by
participant’s perceptions of their susceptibility of having a genetic mutation that would
increase their risk of cancer. These results suggest that women who experience more
discrimination have inflated perceptions of their hereditary cancer risk. Future studies
may wish to explore if this relationship is present with other adult-onset diseases with
genetic risk, such as heart disease or Alzheimer’s disease. Previous studies have shown
that individuals who experience more discrimination are less likely to utilize medical
services. Given that the women in our study who reported more discrimination cited
higher concern about their susceptibility to a mutation as well as increased interest in
testing, strategic outreach to provide counseling services on personalized risk estimates to
this population may aide in decreasing cancer-related anxiety.
Our findings have shown that women from underserved communities and women
who experience more discrimination are equally as interested in genetic testing as other
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participants, but more likely to experience barriers related to education and access that
make obtaining services more difficult. We recommend the inclusion of a genetics
trained health professional on health units designed to reach underserved communities to
aide in counseling on hereditary cancer risk and the process of obtaining genetic testing
to women who qualify as high-risk. Future studies are necessary to determine the
effectiveness of this proposed intervention in increasing the uptake of appropriate testing
in these populations.
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CHAPTER III. CONCLUSIONS
In this study, participants were generally aware of and interested in genetic testing
services. We accept our hypothesis that participants of all backgrounds express similar
levels of interest in genetic testing services. While women from traditionally
underserved populations were less likely to have heard of genetic testing for hereditary
breast cancer prior to this study, they reported similar levels of interest to other
participants in this study.
Notably, there were no significant differences between populations’ agreement
with benefits and barriers regarding the clinical utility of testing, suggesting that even
women who have less exposure to genetic technology are able to perceive the benefit and
personal gain they might receive through predictive risk analysis.
As we expected, women from traditionally underserved populations were more
likely to agree with proposed barriers regarding accessibility. Specifically, women from
these populations agreed significantly more that they were concerned about cost and lack
of awareness of what would be done in genetic testing.
We observed an unanticipated relationship between perceived susceptibility to a
risk increasing genetic mutation and experiences of discrimination. Women who
experience more discrimination may also have increased levels of stress and anxiety that
inflate perceptions of hereditary cancer risk.
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APPENDIX A. PARTICIPANT RESOURCES

LOCATE A GENETIC COUNSELOR
If at any point during this questionnaire you became concerned about your risk of having
a genetic mutation that would increase your chance of having cancer, consider contacting
a local genetic counselor by following the steps below:
1. Go to the National Society of Genetic Counselors website homepage at:
http://www.nsgc.org/
2. On the NSGC homepage, click the link titled, “Find a Genetic Counselor” in the
bottom right hand of the corner of your screen

3. Enter your postal code and make sure to click “Cancer” under specialization.
Then, click search!
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APPENDIX B. INVITATION TO PARTICIPANTS
University of South Carolina School of Medicine
USC Genetic Counseling Program

Dear Potential Participant,
You are invited to participate in a graduate research study focused on women’s
perceptions of the purpose of genetic testing for hereditary breast cancer syndromes. I
am a graduate student in the genetic counseling program at the University of South
Carolina School of Medicine. My research investigates factors that influence women's
interest in genetic testing. This research will involve the completion of this questionnaire,
which will collect information about you and your viewpoints regarding genetic testing
and cancer. Your responses will help genetic counselors and health providers better
understand women's viewpoints regarding genetic testing services and provide these
services to a broader range of women.
All responses gathered from the surveys will be kept anonymous and confidential. The
results of this study might be published or presented at academic meetings; however,
participants will not be identified.
Your participation in this research is voluntary. By completing the questionnaire, you are
consenting that you have read and understand this information. At any time, you may
withdraw from this study by not completing the questionnaire.
If you have any questions regarding this research, you may contact either myself or my
faculty advisor, Crystal Hill-Chapman, Ph.D., using the contact information below.

Taylor Apostolico, BS
(610) 955 9615
taylor.apostolico@gmail.com

Crystal-Hill Chapman, PhD
(843) 661 1721
chillchapman@fmarion.edu

If you have any questions about your rights as a research participant, you may contact the
Office of Research Compliance at the University of South Carolina at (803) 777-7095.
Thank you for your time and consideration to participate in this survey!
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APPENDIX C. LETTER OF SUPPORT
University of South Carolina School of Medicine
USC Genetic Counseling Program
To the University of South Carolina IRB:
I am familiar with Taylor Apostolico’s research project entitled “Assessing Women’s
Attitudes Towards Genetic Testing for Hereditary Breast Cancer”. I understand
[Organization Name] involvement to be permitting interested clients and community
members to be surveyed and distributing questionnaires.
I understand that this research will be carried out following sound ethical principles and
that participant involvement in this research study is strictly voluntary and provides
confidentiality of research data, as described in the protocol.
Therefore, as a representative of [Organization Name] I agree that Taylor Apostolico’s
research project may be conducted at our agency.

Sincerely,

_______________________________
Organization Representative

______________________
Date
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APPENDIX D. BACKGROUND INFORMATION

HEREDITARY
BREAST CANCER
A Brief Introduction
What is Hereditary Breast Cancer?
Breast cancer is a cancer that develops from the breast tissue. It affects 1 in 8 women in
the United States. Typically, this happens by chance. In a small percentage of breast
cancer cases, it is caused by a genetic mutation in one of a few genes. When one of these
genes has a mutation, it stops working leading to an increased risk of cancer. This form
of breast cancer is called hereditary breast cancer.
Two of the more common genes that cause hereditary breast cancer are the BRCA1 and
BRCA2 genes. Women who have mutations in these genes have a higher risk of
developing a few cancers, including breast and ovarian cancer. Around 1-3% of people
in the United States have a mutation in one of these genes. It is possible to test a person’s
blood for the presence of mutations that may cause a person to have an increased chance
of getting breast cancer. For the purpose of this study, this process of obtaining genetic
information related to a person’s risk of having breast cancer will be called ‘genetic
testing for hereditary breast cancer’
What is a Genetic Counselor?
Genetic counselors are trained health care workers that help individuals understand the
many implications of genetic contributions to disease. Genetic counselors use family and
personal histories to determine an individuals’ risk of having a genetic mutation, like one
in a BRCA gene, that would increase the individual's risk of having cancer.
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APPENDIX E. QUESTIONNAIRE
1. Had you heard of genetic testing for hereditary breast cancer before beginning this
survey?
Yes

No

2. Have you personally had genetic testing for hereditary breast cancer before?
Yes

No

3. Is genetic testing for hereditary breast cancer something you would be interested in
pursuing?
Yes

No

4. What do you think your chance is of developing breast cancer in your lifetime? Please
choose a number between 0 (no chance of breast cancer) and 100 (definitely will get
breast cancer)
5. How strongly do you agree or disagree with the following statements?
It is likely that I carry a gene mutation that increases my risk for breast cancer
Strongly Disagree

Disagree

Agree

Strongly Agree

The chances that a gene mutation runs in my family are great
Strongly Disagree

Disagree

Agree

Strongly Agree

6. How strongly do you agree or disagree with the following statements?
If I found out that I carried a gene mutation, it would greatly disrupt my life
Strongly Disagree

Disagree

Agree

Strongly Agree

Finding out I carried a gene mutation would be very difficult for me
Strongly Disagree

Disagree

Agree

Strongly Agree

If I found out I carried a gene mutation, I would worry much more about developing breast
cancer
Strongly Disagree

Disagree

Agree
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Strongly Agree

7. How strongly do you agree or disagree with the following statements?
I am afraid to undergo genetic testing because I may not be able to cope with the result
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing will not tell me anything about my risk I do not already know
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing to learn about my risk will give me a sense of personal control
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing will lead to unfair treatment of some people – that is, discrimination
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing will help me reduce uncertainty about the future
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing will help me decide on the best course of action to take to deal with my
cancer risk
Strongly Disagree

Disagree

Agree

Strongly Agree

My family will not be supportive if I undergo genetic testing
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing will help me learn about my children’s risk for breast cancer
Strongly Disagree

Disagree

Agree

Strongly Agree

Agree

Strongly Agree

I cannot afford the cost for genetic testing
Strongly Disagree

Disagree

Genetic testing will ease my mind, regardless of the test result
Strongly Disagree

Disagree

Agree

Strongly Agree

I am afraid to undergo genetic testing because I do not understand what will be done
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing to learn my risk will help other family members decide whether to undergo
testing
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing will not help me because I would not do anything different to manage my
cancer risk
Strongly Disagree

Disagree

Agree
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Strongly Agree

Genetic testing will have a negative impact on my family
Strongly Disagree

Disagree

Agree

Strongly Agree

Genetic testing will help me make important life decisions (such as getting married, having
children)
Strongly Disagree

Disagree

Agree

Strongly Agree

8. How strongly do you agree or disagree with the following statements?
I can solve most problems if I invest the necessary effort
Strongly Disagree

Disagree

Agree

Strongly Agree

I am confident that I could deal efficiently with unexpected events
Strongly Disagree

Disagree

Agree

Strongly Agree

If I am in trouble, I can usually think of a solution
Strongly Disagree

Disagree

Agree

Strongly Agree

If someone opposes me, I can find the means and ways to get what I want
Strongly Disagree

Disagree

Agree

Strongly Agree

When I am confronted with a problem, I can usually find several solutions
Strongly Disagree

Disagree

Agree

Strongly Agree

It is easy for me to stick to my aims and accomplish my goals
Strongly Disagree

Disagree

Agree

Strongly Agree

Agree

Strongly Agree

I can usually handle whatever comes my way
Strongly Disagree

Disagree

I can always manage to solve difficult problems if I try hard enough
Strongly Disagree

Disagree

Agree

Strongly Agree

Thanks to my resourcefulness, I know how to handle unforeseen situations
Strongly Disagree

Disagree

Agree

Strongly Agree

I can remain calm when facing difficulties because I can rely on my coping abilities
Strongly Disagree

Disagree

Agree

Strongly Agree

9. In your day-to-day life, how often do the following things happen to you?
You are treated with less courtesy or respect
Never

Rarely

Occasionally

Frequently

Occasionally

Frequently

You receive poorer service than other people
Never

Rarely
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People act as if they think you are not smart
Never

Rarely

Occasionally

Frequently

Rarely

Occasionally

Frequently

Rarely

Occasionally

Frequently

People act as if they are afraid of you
Never

You are threatened or harassed
Never

10. Please answer the following questions as either True or False
A father can pass down an altered BRCA gene to his daughters
True

False

All women who have an altered BRCA gene will get cancer
True

False

A woman who has a sister with an altered BRCA gene has a 50% chance of having an altered
BRCA gene herself
True

False

A woman who doesn’t have an altered BRCA gene can still get cancer
True

False

There are many different genes that cause cancer
True

False

The BRCA gene causes about one half of all breast cancers
True

False

11a. Have you ever been diagnosed with cancer?
Yes

No

11b. If so, what type of cancer were you diagnosed with?
11c. If so, at what age(s) were you diagnosed with cancer?
12a. Have you ever had genetic testing for any condition?
Yes

No

12b. If so, what was the reason you had genetic testing?
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13a. Has anyone in your family been diagnosed with breast cancer at any time in their
life?
Yes

No

13b. If so, how many relatives have had breast cancer?
13c. If so, which relative(s) have had breast cancer? Please check all that apply.
Mother
Sister
Daughter
Grandmother (on mother’s side)
Grandmother (on father’s side)

Aunt (on mother’s side)
Aunt (on father’s side)
Cousin (on mother’s side)
Cousin (on father’s side)
Other (please specify)_____________

14. Does your family have Ashkenazi Jewish ancestry?
Yes

No

15. What race do you most identify with?
Alaskan Native
American Indian
Asian
Black American
Hispanic

Native Hawaiian
Non-Hispanic White
Pacific Islander
Other (please specify)_________________

16. What is the highest level of school you have completed or the highest degree you
have received?
Less than high school degree
High school degree or equivalent (e.g., GED)
Some college but no degree
Associate degree
Bachelor degree
Graduate degree

17. What type of health insurance are your currently covered by?
Currently uninsured
Student Health Insurance (provided by University)
Medicare
Medicaid
Employer provided private insurance
Self-provided private insurance

18. Which of the following best describes your current relationship status?
Married
Widowed
Divorced
Separated
In a domestic partnership or civil union
Single, but cohabiting with a significant other
Single, never married
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19. How much total combined money did all members of your household earn last
year?
$0 to $9,999
$10,000 to $24,000
$25,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 to $124,999

$125,000 to $149,999
$150,000 to $174,999
$175,000 to $199,999
$200,000 and up
Prefer not to answer

20. What is your zip code? __________________
21. How many children do you have? _________
22. What is your current age? _________
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